Steven T. Rosen, MD, FACP, director of the Robert H. Lurie Cancer Center of Northwestern University, announced that the Center has received a 4-year grant in the amount of $4.27 million from the US Army Medical Research and Materiel
Steven T. Rosen, MD, FACP, director of the Robert H. Lurie Cancer Centerof Northwestern University, announced that the Center has received a 4-yeargrant in the amount of $4.27 million from the US Army Medical Researchand Materiel Command for a project entitled, "Increasing Access toModern Multidisciplinary Breast Cancer Care."
The principal investigator of the project is Monica Morrow, MD, directorof the Lurie Cancer Center's Clinical Breast Cancer Research Program; associateprofessor, Department of Surgery, Northwestern University Medical School;and director of the Lynn Sage Comprehensive Breast Center at NorthwesternMemorial Hospital.
The award provides funds for eight research projects that focus on accessto breast cancer care by minority women; education of minority women andnonphysician providers who have contact with the medically underserved;dietary intervention to reduce cancer risk; methods to increase minorityparticipation in clinical trials; and the cost-effectiveness of new technologies.
The Robert H. Lurie Cancer Center of Northwestern University, a NationalCancer Institute-designated clinical cancer center, is the focus of cancerresearch, education, and patient care at Northwestern University. The LurieCancer Center coordinates clinical research and cancer patient care programsat the teaching affiliates of the Northwestern University Medical Schooland, through the Northwestern Healthcare Network, is associated with thecancer programs at nine hospitals in the Chicago area.
Experts Discuss Differences in Radiotherapy Outcomes in BRCA+ Breast Cancer
October 30th 2023Rebecca M. Shulman, MD, and Zachary Kiss, DO, discuss findings from a study evaluating differences in outcomes with radiotherapy and disease characteristics of patients with breast cancer harboring BRCA mutations compared with those without mutated disease.
FDA Approves Capivasertib Plus Fulvestrant in Advanced HR+, HER2– Breast Cancer
November 16th 2023Patients with locally advanced or metastatic breast cancer that is hormone receptor–positive, HER2-negative breast cancer with 1 or more PIK3CA, AKT1, or PTEN alterations may now receive capivasertib plus fulvestrant.
Oncology On-The-Go Podcast: De-escalating Breast Cancer Treatment
May 8th 2023Rakhshanda Rahman, MD, FRCS, FACS, emphasizes the importance of educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.